Live
- First Impressions and Unboxing of the MacBook Pro M4: A Powerhouse for Professionals and Creators
- China Gears Up for Potential Trade War Amid Trump’s Tariff Threats
- Small Farmers Gain Less by Selling to Supermarkets: Study Reveals
- Why Despite the Controversy, America Is Anticipating the Mike Tyson vs. Jake Paul Fight
- Sanju Samson and Tilak Varma Shine: Record-Breaking Feats in 4th T20I Against South Africa
- India Urges $1.3 Trillion Annual Climate Support for Developing Nations
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
Aurobindo gets FDA nod for acid reflux drug
Highlights
City-based Aurobindo Pharma on Thursday said it had received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
Hyderabad: City-based Aurobindo Pharma on Thursday said it had received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Famotidine Tablets," the company said in a statement. Approval has been granted for Famotidine Tablets of 20 mg and 40 mg strengths.
The approved ANDA (Abbreviated New Drug Application) is bioequivalent and therapeutically equivalent to the reference listed drug product Pepcid Tablets, 20 mg and 40 mg, of Valeant Pharmaceuticals International, Inc, it added. Famotidine Tablets is used for the short-term treatment of gastroesophageal reflux disease and active duodenal ulcer.
Quoting IMS data, Aurobindo Pharma said the approved product had an estimated market size of $29 million for the twelve months ending October 2015. This is the 54th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products, the company said.
Business Bureau
Next Story
ADVERTISEMENT
